Multiple myeloma (ICD10 C90): combined sexes

Five-year relative survival by diagnosis year and age at diagnosis

	Five-year relative survival (with 95% confidence interval) by diagnosis year				EUROCARE-4	EUROCARE-4
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009	##1995-1999	##1995-1999
	cohort	cohort	cohort	*hybrid	Ireland	Europe average

all 15-99	25.9%	28.9%	41.9%	42.9%
(unstandardized)	(22.1-29.8%)	(25.5-32.3%)	(37.1-46.7%)	(38.1-47.7%)

all 15-99	27.6%	29.6%	42.7%	44.2%	27.7%	35.1%
(age-standardized)#	(18.9-36.5%)	(22.6-36.6%)	(32.8-51.8%)	(33.4-53.1%)	(24.4-31.5%)	(34.3-36.0%)

15-44	47.0%	63.7%	87.7%	94.4%
	(21.4-69.2%)	(46.2-76.9%)	(70.0-95.4%)	(64.0-99.3%)

45-54	46.7%	52.1%	75.2%	75.0%
	(31.6-60.5%)	(41.6-61.6%)	(61.9-84.6%)	(61.7-84.5%)

55-64	26.8%	38.3%	41.9%	41.2%
	(19.8-34.2%)	(30.5-46.0%)	(31.3-52.1%)	(31.4-50.7%)

65-74	23.4%	19.9%	32.3%	34.4%
	(17.4-29.9%)	(15.1-25.3%)	(24.9-40.0%)	(26.6-42.4%)

75-99	19.8%	14.8%	29.4%	31.4%
	(13.7-27.0%)	(10.2-20.3%)	(21.0-38.9%)	(22.5-41.3%)

Footnotes:

*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period,

supplemented by follow-up 2005-2009 for cases diagnosed in 2005 or 2006 (to provide more reliable estimation of the first two years of survival).

In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data.

# Age-standardized figures use the standard patient population proposed for this cancer by:

Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000)

## For comparison, the age-standardized average survival is quoted for countries (including Ireland) that participated in the EUROCARE-4 study:

Sant M. et al. 2009. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991.

Exclusions (as in EUROCARE):

Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient

(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour.